In 2009, the AACC Lipoprotein and Vascular Diseases Division Working Group on Best Practices published a position statement describing why apoB is the best risk marker for clinical practice [6]. In 2013, the same group supported the adoption of apoB measurement in ASCVD risk assessment and favored treatment guidelines that utilized apoB [11]. Recently, an even stronger rationale exists for leveraging the benefits of apoB for ASCVD risk assessment, given the growing number of patients with obesity, type II diabetes mellitus, or the metabolic syndrome. These patients are known to have abnormal lipoprotein profiles, with high triglycerides (TGs), low high-density lipoprotein cholesterol (HDL-C), and elevated small, dense LDL (sdLDL) particle number, but normal or only slightly elevated LDL-C. This profile often leads to discordance between the LDL particle number (LDL-P), for which apoB is a close proxy, and LDL-C, and may lead to erroneous LDL-C-based therapeutic decisions [12,13]. The discordance between apoB and LDL-C is also of particular relevance in statin-treated patients, whose LDL-C and non-HDL-C are reduced to a greater extent than their LDL-P (apoB) [14,15,16].